SCHEDULE: Avidity Partners Reports 5.9% Stake in IMMUNIC

Avidity Partners Management LP and related entities have reported a 5.9% beneficial ownership stake in IMMUNIC, INC. common stock.

Summary

• Avidity Partners Management LP, along with its general partner Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, and Michael Gregory, collectively reported beneficial ownership of 5,615,811 shares of IMMUNIC, INC. common stock.
• This aggregate ownership represents 5.9% of the class of IMMUNIC, INC. common stock.
• Avidity Private Master Fund I LP, a related entity, reported beneficial ownership of 4,699,411 shares, representing 4.9% of the class.
• All reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
• The securities are directly owned by advisory clients of Avidity Partners Management LP, with no single client beneficially owning more than 5% of the common stock.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating previous ownership disclosures by these entities.
• The shares were not acquired and are not held for the purpose of changing or influencing the control of IMMUNIC, INC.

Sentiment

Score: 6

Explanation: The filing is a routine beneficial ownership report indicating a significant institutional stake, which can be viewed as a neutral to slightly positive signal of investor confidence, but it contains no performance or forward-looking financial data.

Positives

• A significant institutional investor, Avidity Partners, maintains a substantial stake in IMMUNIC, INC., which can be interpreted as a signal of continued investor confidence in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional ownership stake by Avidity Partners may be viewed positively, potentially signaling continued investor confidence in IMMUNIC, INC.

Key Dates

Keywords

IMMUNIC, Avidity Partners, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock